Skip to content

RETRIeVE: ReversE TranscRiptase Inhibitor hiV Practice

Non-nucleoside Reverse Transcriptase Inhibitor Failure in a High HIV Caseload Australian Primary Care Practice

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01154556
Enrollment
2044
Registered
2010-07-01
Start date
2010-06-30
Completion date
2013-02-28
Last updated
2015-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV Positive

Keywords

Antiretroviral therapy experienced, failed NNRTI regime

Brief summary

An observational retrospective study of NNRTI experienced patients who have virologically failed. The study aims to assess resistance profiling and subsequent prescription patterns of patients on NNRTIs

Detailed description

This is a cross-sectional study involving retrospective review of HIV-1 positive patient records who began treatment with a non-nucleoside reverse transcriptase inhibitor (NNRTI) and subsequently failed. Patients who have virologically failed previous NNRTI treatment, or have resistance to 1 drug in the NNRTI class are examined further. Such patients will have attended the clinic every 3-6 months for routine medical care. The data source for variables collected is the patient's electronic medical records. This database is located at Holdsworth House Medical Practice (HHMP), Sydney.

Interventions

None listed

Sponsors

Holdsworth House Medical Practice
Lead SponsorOTHER

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

1. Documented HIV infection 2. Attended Holdsworth House Medical Practice 1999-2009. 3. Chosen ART regime includes an NNRTI

Exclusion criteria

N/A

Design outcomes

Primary

MeasureTime frame
resistance profiling and subsequent prescription patterns of patients on NNRTIs1 year

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026